GSK Presents Positive Data for Arexvy, Its Respiratory Syncytial Virus Vaccine, Indicating Protection Over Three RSV Seasons
October 09, 2024
October 09, 2024
LONDON, England, Oct. 9 (TNSres) -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Oct. 8, 2024:
* * *
- GSK's RSV vaccine is the only RSV vaccine with efficacy and safety data available through 3 full seasons, including in people at increased risk
- Safety and reactogenicity data are consistent with previous results from phase III programme
- GSK will continue to provide data on longer te . . .
* * *
- GSK's RSV vaccine is the only RSV vaccine with efficacy and safety data available through 3 full seasons, including in people at increased risk
- Safety and reactogenicity data are consistent with previous results from phase III programme
- GSK will continue to provide data on longer te . . .